The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Sorafenib (Primary) ; Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 14 Feb 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 14 Feb 2023 Planned primary completion date changed from 30 Jun 2022 to 30 Aug 2023.
- 14 Feb 2023 Status changed from not yet recruiting to recruiting.